Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Hepatitis C virus is commona viral infection. Direct-acting antiviral (DAA) oral drugs has been used in treatment of HCVs. the effect of these drugs on male infertility is still under investigation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Male Infertility Genital Diseases Genital Diseases, Male HCV Infertility Infertility, Male Male Urogenital Diseases Urogenital Diseases

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Faculty of Medicine, Benha University, Al Qalyūbīyah, Benha, Egypt

About this study

Semen analysis will be done to male patients with HCV before and after treatment with DAA. The included men will take therapy for 3 months and HCV RNA titter will be evaluated. changes of seminal parameters will be recorded and analyzed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men patients with HCV

Exclusion criteria

Patients with other hepatic disease, endocrinal disorder, malignancy, or urinary tract infection.

Treatment and study plan

Sofosbuvir +daclatasvir+ simeprevir+Ribavirin

Drug

Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months

Primary outcomes

Treatment of HCV

Time frame: 3 months

HCV titer by PCR is below detection level

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Nov 15, 2022
Registry last updated: Feb 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed